AI Image
Thyroid medicine recall receives FDA's highest risk level
AOL.com • • business
Key Points:
- The FDA has upgraded the recall of Vitruvias Therapeutics Inc.'s 30 mg thyroid tablets to a Class I recall, indicating the highest risk level due to potential serious health effects or death.
- The recall involves one lot of tablets distributed nationwide from January to September 2025, with an expiration date of September 30, 2026, totaling about 3,600 units, of which 1,900 were sold.
- The tablets were found to be potentially superpotent, which can cause symptoms of an overactive thyroid such as weight loss, heat intolerance, fatigue, and hypertension.
- Consumers taking the recalled tablets are advised not to stop use without consulting a healthcare provider and can contact Vitruvias Therapeutics for more information via email or phone.
- As of the recall notice on August 24, Vitruvias Therapeutics had not received any reports of adverse events related to the recalled thyroid tablets.
